Discontinuation of atorvastatin use in hospital is associated with increased risk of mortality in COVID-19 patients.
J Hosp Med
; 17(3): 169-175, 2022 03.
Article
in English
| MEDLINE | ID: covidwho-1680403
ABSTRACT
BACKGROUND:
Statins are a commonly used class of drugs, and reports have suggested that their use may affect COVID-19 disease severity and mortality risk.OBJECTIVE:
The purpose of this analysis was to determine the effect of discontinuation of previous atorvastatin therapy in patients hospitalized for COVID-19 on the risk of mortality and ventilation.METHODS:
Data from 146,413 hospitalized COVID-19 patients were classified according to statin therapy. Home + in hospital atorvastatin use (continuation of therapy); home + no in hospital atorvastatin use (discontinuation of therapy); no home + no in hospital atorvastatin use (no statins). Logistic regression was performed to assess the association between atorvastatin administration and either mortality or use of mechanical ventilation during the encounter.RESULTS:
Continuous use of atorvastatin (home and in hospital) was associated with a 35% reduction in the odds of mortality compared to patients who received atorvastatin at home but not in hospital (odds ratio [OR] 0.65, 95% confidence interval [CI] 0.59-0.72, p < .001). Similarly, the odds of ventilation were lower with continuous atorvastatin therapy (OR 0.70, 95% CI 0.64-0.77, p < .001).CONCLUSIONS:
Discontinuation of previous atorvastatin therapy is associated with worse outcomes for COVID-19 patients. Providers should consider maintaining existing statin therapy for patients with known or suspected previous use.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/
COVID-19
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
J Hosp Med
Year:
2022
Document Type:
Article
Affiliation country:
Jhm.12789
Similar
MEDLINE
...
LILACS
LIS